{"product_id":"vyne-vrio-analysis","title":"VYNE Therapeutics Inc. (VYNE): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eDiscover the secret sauce behind VYNE Therapeutics Inc. (VYNE)'s market position. This VRIO analysis distills whether their core assets are truly Valuable, Rare, Inimitable, and Organized (\u0026amp;O4\u0026amp;), offering a sharp, immediate verdict on their sustainable competitive advantage. Read on to see exactly what sets them apart - or where their vulnerabilities lie.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVYNE Therapeutics Inc. (VYNE) - VRIO Analysis: 1. InhiBET™ BET Inhibitor Platform Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eThe InhiBET™ BET Inhibitor Platform Technology represents the core intellectual property for VYNE Therapeutics, aiming to create better treatments than older BET inhibitors. Honestly, the near-term value is tied directly to pipeline progress, which has seen some turbulence in fiscal year 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Differentiated Drug Potential\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe platform's value proposition rests on developing therapies with enhanced selectivity or alternative administration routes. For instance, VYN202, an oral BD2-selective inhibitor from this platform, showed a promising efficacy signal in its Phase 1b psoriasis trial, even with the partial clinical hold for male subjects. Conversely, the locally-administered repibresib gel did not meet primary endpoints in its Phase 2b vitiligo trial, showing the platform's output isn't guaranteed success.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity and Imitability: Scientific Moat\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe specific chemical library and optimization process used to create these selective inhibitors make the platform itself somewhat rare. Replicating this proprietary work is difficult and time-consuming for competitors, suggesting a high barrier to entry for the technology itself. Still, the market for BET inhibitors is competitive, so rarity is relative to the specific design features.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Management Focus and Financial Runway\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eManagement is actively trying to maximize value through a strategic review, which is a clear organizational action. Financially, as of September 30, 2025, VYNE held \u003cstrong\u003e$32.7 million\u003c\/strong\u003e in cash, which they believe funds operations into the first half of 2027. Research and development expenses dropped by \u003cstrong\u003e48.7%\u003c\/strong\u003e in Q3 2025 to \u003cstrong\u003e$5.3 million\u003c\/strong\u003e, reflecting a focus on capital preservation while addressing pipeline hurdles.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO assessment for the platform:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eVRIO Dimension\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eAssessment\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eKey 2025 Context\/Data\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eVYN202 promising signal vs. repibresib mixed results.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eProprietary design overcomes early-generation limitations.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability\u003c\/td\u003e\n    \u003ctd\u003eHigh\u003c\/td\u003e\n    \u003ctd\u003eDifficult to replicate specific chemical library\/optimization.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eModerate\u003c\/td\u003e\n    \u003ctd\u003eCash runway into H1 2027; active strategic review underway.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n    \u003ctd\u003eTemporary Advantage\u003c\/td\u003e\n    \u003ctd\u003eAdvantage hinges on resolving VYN202 hold and securing a partner for repibresib.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is that the temporary advantage is fragile; the net loss improved to \u003cstrong\u003e$7.3 million\u003c\/strong\u003e in Q3 2025, but pipeline setbacks can quickly erode investor confidence and the runway.\u003c\/p\u003e\n\n\u003cp\u003eKey factors influencing the platform's near-term competitive standing:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eVYN202 Phase 1b trial status for male subjects.\u003c\/li\u003e\n  \u003cli\u003eSuccessful navigation of the 12-week non-clinical toxicology study.\u003c\/li\u003e\n  \u003cli\u003eOutcome of the strategic review process.\u003c\/li\u003e\n  \u003cli\u003eAbility to secure a development partner for repibresib.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf onboarding takes 14+ days, churn risk rises, but for a platform, the risk is asset failure.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVYNE Therapeutics Inc. (VYNE) - VRIO Analysis: 2. Repibresib Gel (VYN201) Clinical Data Package\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides data, even if mixed, on a locally-administered treatment for vitiligo, a condition with high unmet need. The data package includes nominally statistically significant effects in certain secondary endpoints.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNominally Statistically Significant Percent Change from Baseline (CFB) in F-VASI score at week 24 for Repibresib 3% vs. Vehicle: \u003cstrong\u003e-43.6%\u003c\/strong\u003e versus \u003cstrong\u003e-25.6%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNominally Statistically Significant Percent CFB in T-VASI score at week 24 for Repibresib 3% vs. Vehicle: \u003cstrong\u003e-28.3%\u003c\/strong\u003e versus \u003cstrong\u003e-16.2%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; having Phase 2b data, even with a missed primary endpoint, is rarer than just a discovery asset. The trial evaluated \u003cstrong\u003e177\u003c\/strong\u003e subjects.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the specific trial results and patient data are unique to VYNE.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Low; the need to seek a development partner post-Phase 2b readout shows the organization is not fully equipped to commercialize alone. The company will terminate the extension phase of the trial and plans to seek an external development and commercialization partner for Repibresib.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Marketable Securities (as of 2025-09-30)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$32.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway (based on 2025-09-30 figures)\u003c\/td\u003e\n\u003ctd\u003eInto first half of \u003cstrong\u003e2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenues (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the data package's value is eroding as time passes without a clear path forward. Repibresib has patent protection until at least \u003cstrong\u003e2042\u003c\/strong\u003e in the US.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Endpoint\u003c\/td\u003e\n\u003ctd\u003eResult Status\u003c\/td\u003e\n\u003ctd\u003eRepibresib 3% vs. Vehicle (Week 24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Endpoint (F-VASI50)\u003c\/td\u003e\n\u003ctd\u003eMissed\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Secondary Endpoint (F-VASI75)\u003c\/td\u003e\n\u003ctd\u003eMissed\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey Secondary Endpoint (% CFB in F-VASI)\u003c\/td\u003e\n\u003ctd\u003eNominally Statistically Significant\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-43.6%\u003c\/strong\u003e vs. \u003cstrong\u003e-25.6%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003eDropout Rate in Active Arms (Repibresib 3%): \u003cstrong\u003e36.6%\u003c\/strong\u003e compared to Vehicle: \u003cstrong\u003e10.6%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eApplication Site Pain (TEAE) for Repibresib 3% dose: \u003cstrong\u003e14.0%\u003c\/strong\u003e versus Vehicle: \u003cstrong\u003e3.8%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDiscontinuations due to Adverse Event: \u003cstrong\u003eEight\u003c\/strong\u003e patients on repibresib versus \u003cstrong\u003ezero\u003c\/strong\u003e in the vehicle group.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVYNE Therapeutics Inc. (VYNE) - VRIO Analysis: 3. VYN202 Program \u0026amp; Selectivity Profile\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Represents a potential oral treatment for immune-mediated diseases, offering a different mechanism than repibresib.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; a BD2-selective inhibitor profile is less common than pan-BET inhibitors. VYN202 has been designed to achieve class-leading selectivity ($\\text{BD2}$ vs. $\\text{BD1}$) and demonstrated blood levels within key inhibitory thresholds ($\\text{IC50}$ to $\\text{IC90}$ against $\\text{BD2 BRD4}$) for at least \u003cstrong\u003e24 hours\u003c\/strong\u003e following once-daily dosing in Phase 1a MAD data.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: High; the specific molecule and its preclinical\/early clinical data are hard to copy. The molecule is structurally distinct from VYNE's pan-BET inhibitor ($\\text{VYN201}$) and covered by distinct $\\text{PCT}$ and provisional composition of matter patent applications.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Low; the ongoing clinical hold due to dog testicular toxicity severely hampers the organization's ability to exploit this asset now. Financial metrics as of the latest reports include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Value\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on Hand\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$32.7 Million USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.32 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (LTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$524,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast 12 Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (LTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$33.67 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast 12 Months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$36.1M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.87\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Reported\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003ePreliminary Phase 1b efficacy and safety data from the limited cohort prior to the hold included:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubjects Treated (VYN202)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses Tested (mg)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.25, 0.5, 1\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePASI Score Reduction (Week 1 Max)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~27%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePASI Score Reduction (Week 8 Max)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCytokine Reduction Range (IL17A, IL17F, IL19, IL22)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-17% to -83%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSerious Adverse Events\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Discontinuations (due to AE)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; the advantage is entirely dependent on successfully resolving the $\\text{FDA}$ hold via the ongoing toxicology study. Key details regarding the hold include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eClinical Hold issued in \u003cstrong\u003eApril 2025\u003c\/strong\u003e following testicular toxicity in dogs from a non-clinical study.\u003c\/li\u003e\n\u003cli\u003eThe $\\text{FDA}$ lifted the clinical hold for \u003cstrong\u003efemale patients\u003c\/strong\u003e at the \u003cstrong\u003e0.25 mg\u003c\/strong\u003e and \u003cstrong\u003e0.5 mg\u003c\/strong\u003e doses.\u003c\/li\u003e\n\u003cli\u003eThe \u003cstrong\u003e1 mg\u003c\/strong\u003e dose was not included in the revised protocol due to a lower toxicological safety margin.\u003c\/li\u003e\n\u003cli\u003eA \u003cstrong\u003e12-week\u003c\/strong\u003e non-clinical toxicology study in dogs is required to resume the trial in \u003cstrong\u003emale\u003c\/strong\u003e clinical subjects.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVYNE Therapeutics Inc. (VYNE) - VRIO Analysis: 4. Zero Net Debt Balance Sheet\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides financial flexibility and stability, as the company has \u003cstrong\u003e$0.0\u003c\/strong\u003e in total debt, meaning no mandatory interest payments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; for a clinical-stage biotech, having zero debt is quite rare and a major strength.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; competitors often carry significant debt loads to fund trials.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the organization has clearly managed its capital structure to remain debt-free.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; as long as they maintain this structure, it's a sustained advantage in risk management.\u003c\/p\u003e\n\u003cp\u003eThe financial position as of September 30, 2024, demonstrates a debt-free structure:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric (USD in Millions)\u003c\/th\u003e\n\u003cth\u003eValue (Sep 30, 2024)\u003c\/th\u003e\n\u003cth\u003eSource Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDebt-to-equity ratio is \u003cstrong\u003e0%\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.04\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal current liabilities were \u003cstrong\u003e$4.04 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Shareholder Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$32.09\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal shareholder equity was \u003cstrong\u003e$32.1M\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$36.13\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal assets were \u003cstrong\u003e$36.13M\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Restricted Cash, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal cash position as of September 30, 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (Condensed Balance Sheet)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.272\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported as \u003cstrong\u003e$16,272 thousand\u003c\/strong\u003e in the Condensed Consolidated Balance Sheets.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe absence of long-term liabilities is a key component of this structure:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLong Term Liabilities: \u003cstrong\u003e$0.0\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eShort Term Assets (\u003cstrong\u003e$35.9M\u003c\/strong\u003e) exceed Short Term Liabilities (\u003cstrong\u003e$4.0M\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eThe company reported a Net Cash position of \u003cstrong\u003e$32.70 million\u003c\/strong\u003e based on one cash figure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe organization's capital management is reflected in the historical trend:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDebt to Equity Ratio History: The current \u003cstrong\u003e0%\u003c\/strong\u003e compares to a debt to equity ratio of \u003cstrong\u003e66.7%\u003c\/strong\u003e five years ago.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVYNE Therapeutics Inc. (VYNE) - VRIO Analysis: 5. Cash Runway into First Half of 2027\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: The \u003cstrong\u003e$32.7 million\u003c\/strong\u003e cash position as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e, provides a runway into the \u003cstrong\u003efirst half of 2027\u003c\/strong\u003e, covering key milestones.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; a runway extending over \u003cstrong\u003e18 months\u003c\/strong\u003e is good, but not unheard of for companies that have recently raised capital.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Low; this is a function of past financing and current cost control, not an inherent trait.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: High; management has successfully managed cash burn, evidenced by reductions in operating expenses.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; this runway is finite and will be depleted unless new financing or partnerships are secured.\u003c\/p\u003e\n\u003cp\u003eThe operational efficiency contributing to the extended runway is detailed in the comparative financial metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 Ended September 30, 2025\u003c\/th\u003e\n\u003cth\u003eQ3 Ended September 30, 2024\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (as of period end)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$32.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A (Q2 2025 was $39.6 million)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-48.7%\u003c\/strong\u003e (or \u003cstrong\u003e$5.0 million\u003c\/strong\u003e decrease)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral \u0026amp; Administrative Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-8.7%\u003c\/strong\u003e (or \u003cstrong\u003e$0.3 million\u003c\/strong\u003e decrease)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImprovement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(0.17)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$(0.29)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eImprovement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther details supporting the organizational effectiveness in cash management include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003cstrong\u003e$5.0 million\u003c\/strong\u003e decrease in Research and Development expenses for Q3 2025 compared to Q3 2024 was primarily driven by decreased expenses for repibresib (\u003cstrong\u003e$3.9 million\u003c\/strong\u003e) and VYN202 (\u003cstrong\u003e$1.0 million\u003c\/strong\u003e), partially offset by a \u003cstrong\u003e$1.0 million\u003c\/strong\u003e milestone payment made to Tay for VYN202.\u003c\/li\u003e\n\u003cli\u003eThe decrease in VYN202 expenses was due to decreased clinical expenses for Phase 1 trials.\u003c\/li\u003e\n\u003cli\u003eThe decrease in repibresib expenses was primarily driven by the timing of expenses for the Phase 2b trial in nonsegmental vitiligo, including the decision to terminate the trial.\u003c\/li\u003e\n\u003cli\u003eTotal common shares issued and outstanding as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e31,772,904\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOutstanding pre-funded warrants to purchase common stock as of \u003cstrong\u003eSeptember 30, 2025\u003c\/strong\u003e: \u003cstrong\u003e11,059,574\u003c\/strong\u003e at an exercise price of \u003cstrong\u003e$0.0001\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVYNE Therapeutics Inc. (VYNE) - VRIO Analysis: 6. Finacea® Royalty Stream\n\u003c\/h2\u003e\n\u003cp\u003eThe Finacea® Royalty Stream represents a contractual revenue source derived from the prior licensing of the Finacea® foam asset to LEO Pharma A\/S.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe stream provides a small, non-dilutive revenue source. Revenues totaled \u003cstrong\u003e$0.2 million\u003c\/strong\u003e for the three months ended September 30, 2025, compared to \u003cstrong\u003e$0.1 million\u003c\/strong\u003e for the three months ended September 30, 2024.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePeriod End Date\u003c\/th\u003e\n\u003cth\u003eRoyalty Revenue (Millions USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeptember 30, 2025 (Q3)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeptember 30, 2024 (Q3)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJune 30, 2024 (6 Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.3\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecember 31, 2024 (Full Year)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.5\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; this is a reliable, albeit small, income stream common among biopharmaceutical entities with legacy licensing arrangements.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; the revenue stream is secured by a binding contract with LEO Pharma A\/S.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; the company is organized to efficiently collect and account for this specific revenue stream.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eVRIO Assessment Summary:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Present, evidenced by \u003cstrong\u003e$0.2 million\u003c\/strong\u003e in revenue for Q3 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e High, due to contractual lock-in with LEO Pharma A\/S.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e High, demonstrated by consistent accounting and collection.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained; this is a contractual asset that is expected to persist until the agreement's termination date.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVYNE Therapeutics Inc. (VYNE) - VRIO Analysis: 7. Management's Strategic Review Process\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The formal August 2025 initiation signals an active, disciplined approach to finding the best path for shareholder value, including partnerships or sales. The review follows the July 2025 termination of the repibresib Phase 2b trial extension. The Q3 2025 Net Loss was reported at $7.28 million, a reduction from the $12.2 million loss in Q3 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many companies in this position undertake a review, but the timing relative to the data readouts is key. The review is concurrent with the ongoing 12-week, non-clinical toxicology study for VYN202 in dogs, initiated to remedy the partial clinical hold in male subjects.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the specific options being evaluated are internal and confidential. The options under evaluation include strategic partnerships, licensing opportunities, merger or acquisition transactions, and asset sales.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the Board's decision to launch this review shows organizational alignment on capital preservation and value creation. Cost reductions implemented are expected to extend the cash runway into the first half of 2027.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage exists only until the review concludes with a definitive action. The median 12-month Wall Street price target is $3.25 relative to a recent share price of $0.34 (as of November 5, 2025).\u003c\/p\u003e\n\n\u003cp\u003eKey financial metrics underpinning the strategic review timeline:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 (as of 9\/30\/25)\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss (in millions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.28\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents \u0026amp; Marketable Securities (in millions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$32.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Expectation\u003c\/td\u003e\n\u003ctd\u003eInto \u003cstrong\u003eH1 2027\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePrior expectation: \u003cstrong\u003eH2 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (3 months, in millions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe strategic review is evaluating alternatives for pipeline assets, including:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAssessment of internal pipeline opportunities for VYN202.\u003c\/li\u003e\n\u003cli\u003eSeeking an external partner for continued development of repibresib gel following the July 2025 topline results.\u003c\/li\u003e\n\u003cli\u003eEvaluation of financing opportunities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe Company's market capitalization as of December 8, 2025, was $12.44 million, with 33.29 million shares outstanding.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVYNE Therapeutics Inc. (VYNE) - VRIO Analysis: 8. Experience in Navigating FDA Clinical Holds\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The team possesses direct, recent experience managing an FDA clinical hold concerning VYN202, stemming from an observation of testicular toxicity in canine non-clinical studies, which occurred in April 2025. The company suspended all screening, enrollment, and patient dosing in the Phase 1b trial. Resolution efforts have resulted in the clinical hold being lifted for female patients at the 0.25 mg and 0.5 mg dose levels. The initial Phase 1b trial involved n=6 treated subjects across 0.25 mg, 0.5 mg, and 1 mg doses before the hold.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while clinical holds are not uncommon in the biotechnology sector, the specific process for addressing a testicular toxicity signal from a non-clinical study for a BD2-selective BET inhibitor is specialized.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; the knowledge gained from the direct, high-stakes interaction with the FDA to navigate the hold, including protocol amendments and initiating specific follow-up studies, constitutes tacit knowledge that is difficult to replicate quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company demonstrated organizational response by immediately suspending dosing and initiating the required non-clinical study to address the FDA's concerns. Financial planning adjusted, with the cash runway extended into the first half of 2027 based on previously announced cost reductions following the hold. The company's Research and Development expenses related to VYN202 decreased by $1.0 million for the three months ended September 30, 2025, compared to the prior year, partially offset by a $1.0 million milestone payment made to Tay in Q3 2025 under the VYN202 License Agreement amendment.\u003c\/p\u003e\n\u003cp\u003eThe specific actions and status related to the hold management are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\/Action\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHold Trigger\u003c\/td\u003e\n\u003ctd\u003eTesticular toxicity in dogs from non-clinical toxicology study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Trial Status\u003c\/td\u003e\n\u003ctd\u003ePhase 1b study for moderate-to-severe plaque psoriasis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing Suspension\u003c\/td\u003e\n\u003ctd\u003eAll screening, enrollment, and patient dosing suspended.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHold Resolution Step\u003c\/td\u003e\n\u003ctd\u003eInitiated repeat 12-week, non-clinical toxicology study in dogs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHold Status (Latest)\u003c\/td\u003e\n\u003ctd\u003ePartial hold remains for male clinical subjects; lifted for female patients at 0.25 mg and 0.5 mg.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDose Excluded\u003c\/td\u003e\n\u003ctd\u003e1 mg dose excluded from revised protocol due to lower safety margin.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the value of this specific experience is high while the partial clinical hold for male subjects remains in effect and the repeat toxicology study is ongoing. The advantage diminishes upon successful resolution of the hold and subsequent advancement of VYN202 in clinical development.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVYNE Therapeutics Inc. (VYNE) - VRIO Analysis: 9. Proprietary Small Molecule Chemistry Expertise\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This is the foundation that created both the InhiBET™ platform and the distinct VYN201 and VYN202 molecules.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while many biotechs have chemistry expertise, the specific focus on BET inhibitors is more niche.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; the deep, institutional knowledge of this specific chemical space is not easily replicated by hiring a few new chemists.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; this expertise is embodied in key personnel, but the organization needs to retain them to exploit it.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; fundamental scientific expertise is a long-term, hard-to-imitate asset.\u003c\/p\u003e\n\n\u003cp\u003eThe proprietary chemistry underpins the development of the BET inhibitors, VYN201 (Repibresib) and VYN202, which are central to the current pipeline.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003ctd\u003eSource Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Restricted Cash and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2024\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 Balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$61.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003ctd\u003eYear-End 2024 Balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Balance (Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 2025\u003c\/td\u003e\n\u003ctd\u003eLatest Reported Balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrailing Twelve Months Cash Burn\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$38 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of March 2025\u003c\/td\u003e\n\u003ctd\u003eAnnualized Burn Rate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003eQuarterly Spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear Ended December 31, 2024\u003c\/td\u003e\n\u003ctd\u003eAnnual Spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey pipeline assets directly resulting from this expertise include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eVYN201 (Repibresib gel), a locally-administered pan-BD BET inhibitor, with a Phase 2b trial in nonsegmental vitiligo enrolling approximately \u003cstrong\u003e40 to 50 subjects\u003c\/strong\u003e per arm.\u003c\/li\u003e\n\u003cli\u003eVYN202, an oral BD2-selective BET inhibitor, which completed its Phase 1a SAD\/MAD trial in Q4 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e The latest reported cash balance as of March 2025 was \u003cstrong\u003e$50 million\u003c\/strong\u003e, with a trailing twelve months cash burn of \u003cstrong\u003e$38 million\u003c\/strong\u003e as of that date. The Q3 2024 cash balance was \u003cstrong\u003e$70.2 million\u003c\/strong\u003e.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516281872533,"sku":"vyne-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vyne-vrio-analysis.png?v=1740230406","url":"https:\/\/dcf-model.com\/products\/vyne-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}